Cross-resistance between cisplatin (DDP) and metalloid salts in human cells was sought on the basis that mechanisms that mediate metalloid salt cross-resistance in prokaryotes are evolutionarily conserved. Two ovarian and two head and neck carcinoma cell lines selected for DDP resistance were found to be cross-resistant to antimony potassium tartrate, which contains trivalent antimony. The DDP-resistant variant 2008/A was also cross-resistant to arsenite but not to stibogluconate, which contains pentavalent antimony. A variant selected for resistance to antimony potassium tartrate was cross-resistant to DDP and arsenite. Resistance to antimony potassium tartrate and arsenite was of a similar magnitude (3-7-fold), whereas the level of resistance to DDP was greater (17-fold), irrespective of whether the cells were selected by exposure to DDP or to antimony potassium tartrate. In the resistant sublines, uptake of [3H] -dichloro(ethylenediamine) platinum(ll) was reduced to 41-52% of control, and a similar deficit was observed in the accumulation of arsenite. We conclude that DDP, antimony potassium tartrate, and arsenite all share a common mechanism of resistance in human cells and that this is due in part to an accumulation defect. (J. Clin. Invest. 1995.
Introduction
Among several proposed mechanisms for natural and acquired resistance to cisplatin (DDP),' decreased drug accumulation is the most consistent finding both in vivo (1) and in vitro (2) (for reviews see references [3] [4] [5] [6] [7] . The cause of this impairment in DDP accumulation is unknown, and in fact, the mechanism by which DDP enters or exits from cells remains poorly defined. DDP enters cells relatively slowly compared with the anticancer agents that participate in the multidrug-resistant phenotype, and at least one component of DDP uptake is likely to be mediated by a transport mechanism or channel (6) (7) (8) (9) (10) . DDP efflux is even slower, and it has been difficult to distinguish any major differences in efflux pattern between sensitive and resistant cell lines (11) (12) (13) .
Several transport-protein complexes that mediate the detoxification of heavy metal salts have been identified in bacteria and yeast and appear to be structurally and functionally well conserved throughout evolution (14) (15) (16) (17) (18) (19) (20) . During studies directed at identifying metal salts that demonstrated a pattern of cross-resistance similar to that of DDP, we found that a DDPselected subline of the human ovarian carcinoma 2008 line was cross-resistant to antimony potassium tartrate, and an antimony potassium tartrate-selected variant was cross-resistant to DDP (Naredi, P., and S. B. Howell, unpublished data). In both resistant variants, there was an impairment of the uptake of the DDP analog [ 3H ] -cis-dichloro (ethylenediamine) platinum(II) ( [3H] DEP). Antimony potassium tartrate contains antimony in a trivalent form, and one mechanism of resistance to trivalent antimonials in bacteria is mediated by genes that make up the ars operon (21 ) . In Escherichia coli and Staphylococcus aureus, this operon codes for a specific efflux-transport system that can export oxyanions of antimony but is best known for its ability to confer resistance to arsenic oxyanions (21) . In the protozoa Leishmania, the Impgp gene has also been reported to confer resistance to both antimony potassium tartrate and arsenite (19) .
The aim of this study was to determine the extent to which human ovarian carcinoma cells selected for resistance to DDP are cross-resistant to oxyanions that share a common mechanism of resistance in bacteria. The results indicated that cells selected for resistance to DDP were cross-resistant not only to antimony potassium tartrate, but also to arsenite (see Fig. 1 (24) . UMSCC5 and UMSCCIOb were derived from human squamous cell carcinomas in the head and neck region (25, 26) . The DDP-resistant UMSCC5/DDP and UMSCClOb/DDP lines were selected by chronic exposure to DDP with incremental increases in DDP concentration to 0.6 and 0.8 MM, respectively, over 5 mo (27) . The present studies were performed after cells had been passaged in drugfree media a minimum of three times. The cells were grown on tissue culture dishes in a humidified incubator at 37°C in a 5% CO2 atmosphere. They were maintained in complete medium consisting of RPMI 1640 (Irvine Scientific, Santa Ana, CA) supplemented with 5% (10% for UMSCC cells) heat-inactivated FCS and 2 mM glutamine. Cultures were routinely tested for mycoplasma using a kit from Gen Probe Inc. (San Diego, CA) and were found to be negative.
Clonogenic psM, indicating that they were 6.6-fold resistant compared with the parental 2008 cells. They were also 16± 1-fold cross-resistant to DDP (P < 0.05) and 4.3±0.5-fold cross-resistant to sodium arsenite (P < 0.05), but were not cross-resistant to stibogluconate. Thus, each of the predictions was substantiated, arguing strongly for a common underlying mechanism of resistance. Previous studies with DDP-selected variants of 2008 cells had demonstrated impaired uptake of both DDP (2, 9, 1 1 ) and an analog of DDP, DEP, which can be labeled to high specific activity with 3H (30). Fig. 3 (top panel) resistant phenotype impacted exclusively on accumulation and had no discernable effect on efflux.
Discussion
The results reported here disclose a novel aspect of the DDPresistant phenotype by demonstrating that the phenotype includes cross-resistance to antimony potassium tartrate and arsenite. The DDP-resistant phenotype has been characterized in several human carcinomas, both in vitro and in vivo, and in some circumstances, it has been shown to include cross-resistance to gamma radiation, UV light, other heavy metals and platinum-containing drugs, methotrexate, and alkylating agents (for reviews see references 3-5). However, DDP resistance is not accompanied by resistance to drugs that participate in the multidrug-resistant phenotype mediated by the mdrl gene product (31, 32) ; nor has it previously been reported to be accompanied by resistance to antimony-or arsenic-containing agents. In this study, four different human DDP-resistant tumor cell lines representing two different histologic types of cancer were found to be cross-resistant to antimony potassium tartrate. There was a correlation between the level of DDP resistance and the P. Naredi, D. D. Heath, R. E. Enns, and S. B. Howell The mechanism by which DDP enters or exits from cells remains poorly defined (3) . DDP uptake is not saturable within the limits of its solubility in tissue culture medium, which argues that either DDP enters cells by passive diffusion, or saturation occurs only at concentrations above its maximum solubility ( 11, 33) . Thus far, no membrane changes of a magnitude sufficient to account for the observed decrease in uptake due to a change in passive diffusion of DDP have been found in DDP-resistant 2008 sublines (34) . On the other hand, there is increasing evidence that DDP accumulation is mediated in part by an active transporter or channel that is dependent on a functional (Na+/ K+ ) -ATPase, membrane potential, extracellular pH, and extracellular osmolality (for review see reference 3). In addition, DDP accumulation can be inhibited by -50% by a variety of agents (8) . Current evidence supports a model of DDP accumulation that involves contributions from both passive diffusion and a transporter or gated channel (3) . Although antimony potassium tartrate and stibogluconate have structures quite different from those of cisplatin and sodium arsenite, the structure of the former two drugs in an aqueous environment is not known, and it is unclear what form of the drug is actually taken up into the cell. At physiologic pH, DDP probably crosses the membrane as a neutral drug and arsenite is present largely as arsenous acid (As (OH)3), which is also neutral. There is a strong suspicion that antimony potassium tartrate and stibogluconate come apart in an aqueous environment and that they cross the membrane as oxyanions, but no information is currently available as to the actual charge or molecular weight of the form that gets into the cell.
Impairment in arsenite accumulation, as well as that of antimony potassium tartrate, is also observed in drug-resistant strains of bacteria and the promastigote Leishmania; however, in these organisms, the impaired accumulation is due to enhanced efflux rather than decreased influx. In bacteria there is a welldefined plasmid-encoded efflux system belonging to the ATPbinding cassette family that exports arsenite and metabolites of antimony potassium tartrate. The efflux transporter consists of the membrane-spanning subunit, ArsB, a specific protein for the reduction of pentavalent anions to the trivalent state, ArsC, and in gram-negative bacteria, also a third protein, ArsA, with ATPase activity (21, 35) . No example of resistance due to decreased influx of arsenite or antimony-containing anions has been reported in bacteria. In fact, whereas pentavalent arsenic (arsenate) is known to be taken up by the phosphate transport system in both bacteria and human cells (21, 36) , nothing is known about the uptake of the trivalent forms of arsenic and antimony, such as arsenite and antimony potassium tartrate.
In the protozoa Leishmania, the lmpgp gene has been reported to confer resistance to the trivalent antimony compound antimony potassium tartrate, but not to stibogluconate, which contains antimony in the pentavalent state (19) . In contrast, resistance of Leishmania to pentavalent antimonials has been associated with the expression of a P-glycoprotein-like molecule coded for by the ItpgpA gene (37) , and such resistance can be reversed by verapamil (38). Stibogluconate-resistant Leishmania were reported to accumulate two to five times less
[125Sb] stibogluconate than sensitive clones, and the P-glycoprotein-specific antibody C219 detected a protein in Leishmania whose molecular weight was the same as that of P-glycoprotein in the multidrug-resistant human KB carcinoma sublines (39) . Thus, the phenotype generated by amplification of the Impgp gene appears to be closer to the RASP phenotype in human cells than that produced by the ltpgpA gene.
The discovery that the DDP-resistant phenotype also includes resistance to antimony potassium tartrate and arsenite begs the question of whether this form of resistance extends to other metalloid salts, such as selenite or tellurite, in particular because biochemical mechanisms for the detoxification of several of these salts are well described and may be relevant to the detoxification of DDP in some tissues. The fact that the phenotype includes impaired uptake of arsenite is also of interest because it provides an additional putative substrate for the DDP uptake pathway, available in an easily usable radiolabeled form, with which to study the specificity of the accumulation mechanism.
